Bank of New York Mellon
LXEO icon

Bank of New York Mellon’s Lexeo Therapeutics LXEO Stock Holding History

Bank of New York Mellon’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
183,883
+24,984
+16% +$135K ﹤0.01% 3455
2026
Q1 		$912K Sell
158,899
-7,850
-5% -$55.6K ﹤0.01% 3267
2025
Q4 		$1.66M Buy
166,749
+95,072
+133% +$868K ﹤0.01% 2953
2025
Q3 		$476K Buy
71,677
+6,525
+10% +$31.6K ﹤0.01% 3625
2025
Q2 		$262K Buy
65,152
+14,508
+29% +$47.7K ﹤0.01% 3867
2025
Q1 		$176K Sell
50,644
-16
-0% -$71 ﹤0.01% 3917
2024
Q4 		$333K Buy
50,660
+2,677
+6% +$21.1K ﹤0.01% 3725
2024
Q3 		$434K Buy
47,983
+16,177
+51% +$193K ﹤0.01% 3593
2024
Q2 		$510K Buy
31,806
+3,483
+12% +$50.6K ﹤0.01% 3577
2024
Q1 		$444K Buy
28,323
+14,213
+101% +$222K ﹤0.01% 3603
2023
Q4 		$189K Buy
+14,110
New +$175K ﹤0.01% 3969

Other funds holding LXEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's LXEO Position: Q2 2026 in Review

Bank of New York Mellon increased its Lexeo Therapeutics (LXEO) stake by 16% in Q2 2026, buying an estimated $135K and bringing the position to 183,883 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

Bank of New York Mellon first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.66M in Q4 2025. 56 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Bank of New York Mellon held 183,883 shares of Lexeo Therapeutics worth $856K as of Q2 2026.
  • Bank of New York Mellon bought 24,984 Lexeo Therapeutics shares in Q2 2026, an estimated $135K.
  • Lexeo Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3455 holding.
  • Bank of New York Mellon first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Bank of New York Mellon's Lexeo Therapeutics position peaked at $1.66M in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.